Posts

AlgiPharma collaboration with Cardiff University wins Medical Innovation Award

A long standing collaboration between AlgiPharma and Professor David Thomas team at the School of Dentistry has been recognized this year by Cardiff University’s prestigious Medical Innovation Award. The award was presented by Dr. Rob Docherty on behalf of Cardiff University.

 

 

Click here for more information and link to the video

 

 

 

(Left to Right) Dr. Manon Pritchard (Cardiff), Dr. Phil Rye (AlgiPharma), Dr Rob Docherty (presenting the award), Prof. David Thomas (Cardiff), Dr. Katja Hill (Cardiff), Dr. Saira Khan (Cardiff), Mr Arne Dessen (AlgiPharma), Dr. Lydia Powell (Cardiff).

 

AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG

Sandvika, Norway, June 3, 2016. AlgiPharma AS today announced an agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), Bethesda, Md., to help fund the development of its inhalable dry powder, OligoG, which has been shown to improve the properties of mucus from the CF lungs and the effectiveness of some antibiotics in early research studies. Research to date suggests that OligoG will help people with cystic fibrosis clear mucus from their lungs and potentially slow the progression of the disease.

To expedite development of OligoG for people with cystic fibrosis, CFFT committed more than $4 million to AlgiPharma. This is in addition to almost $6.9 million that CFFT has awarded so far for a Phase 2 clinical trial, bringing CFFT’s commitment to nearly $11 million.

CFFT is the nonprofit drug discovery and development arm of the Cystic Fibrosis Foundation.

AlgiPharma is currently in Phase 2 clinical trials with OligoG as a dry powder for inhalation. Two clinical trials are ongoing in Europe (recruiting in UK, Germany, Sweden, Denmark and Norway) evaluating the safety and tolerability of OligoG, and include primary endpoints to assess efficacy in individuals with CF.

OligoG works to return thick, sticky mucus toward normal, allowing it to be cleared more easily from the lungs. OligoG also may disrupt the infectious biofilm often present in the lungs of individuals with CF. Biofilm disruption might also improve antibiotic effectiveness by increasing exposure of bacteria to antibiotics.

Yngvar P. Berg, CEO of AlgiPharma, commented on the award: “We are honored and delighted that Cystic Fibrosis Foundation Therapeutics recognizes the unique therapeutic potential of our drug candidate by further supporting the development of OligoG. This CFFT award enables us to accelerate the clinical development of OligoG, and we really appreciate working with CFFT on the remaining clinical development path in bringing this new drug to people with cystic fibrosis.”

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs. This excessive sticky mucus in the lungs becomes a site for infections that can require hospitalization. Respiratory distress in CF — defined as acute difficulty in breathing, infection and/or hospitalization — is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

For more information on CF, please visit www.cff.org.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, based on research and development carried out by FMC BioPolymer AS and the Biopolymer Foundation at the Norwegian University of Science and Technology in Trondheim, Norway, over decades. AlgiPharma was founded in August 2006.

AlgiPharma’s aim is to address unmet medical needs, fighting diseases effectively through its innovative alginate oligomer technologies, by developing products and therapies to market or license to suitable partners.

AlgiPharma AS owns or licenses all relevant patents upon which the technology platform and products are developed.

AlgiPharma AS is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma AS is a privately owned company registered and domiciled in Norway. For additional information, please visit www.algipharma.com

 

Contact:

Yngvar P. Berg, CEO: +47 67545770,  yngvar.berg@algipharma.com

June 3rd 2016

A pdf of this press release can be found here: AlgiPharma press release June 3, 2016

A Norwegian version of this press release can be found here: AlgiPharma press release June 3, 2016 Norwegian

The CFFT press release can be found here: CFFT press release June 3, 2016.

AlgiPharma features in CFF drug development pipeline

AlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline. The CFF interactive drug development pipeline shows the progress of potential CF treatments through the different phases of clinical research. AlgiPharma’s listing in the pipeline of CF drug development reflects the progress and potential for its mucus altering and biofilm disruption alginate oligomer therapy.

Click here to find more information about the CFF interactive drug development pipeline.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

May 4th 2016

AlgiPharma granted Orphan Drug designation by FDA

AlgiPharma was granted Orphan Drug designation by the FDA for its sodium alginate oligosaccharide, OligoG in the treatment of cystic fibrosis (CF).

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

 

February 24, 2016

AlgiPharma starts two new Phase IIb trials in Cystic Fibrosis

AlgiPharma has started preparations for two new clinical phase 2b trials in cystic fibrosis patients. The two studies are:

“A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.”

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

“A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization with Burkholderia spp.”

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Philip D Rye, R&D Director; phil.rye@algipharma.com

February 2015

AlgiPharma awarded four year grant from Norwegian Research Council

AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”. This study will focus on extended long term safety studies and formulation changes to further develop the AlgiPharma drug candidate OligoG for the treatment of cystic fibrosis.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

February 2015

AlgiPharma wins research grant from CFF

AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine. The grant is administered by the Cystic Fibrosis Foundation Therapeutics Inc., a subsidiary of the CFF. The research shall be performed in the United Kingdom.

About the Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, MD, USA, the Foundation funds CF research, has 80 chapter and branch offices throughout the United States, and supports and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
To advance the search for a cure, CFF has invested nearly $230 million in promising scientific research in the pharmaceutical and biotechnology industries since 1998. As a result, the Foundation has nearly 30 potential therapies in its drug discovery and development pipeline. Any one of these could have a profound impact on the lives of people with cystic fibrosis.

For further information, please contact:
Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

April 2011

AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

April 2011

AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more ClinicalTrials.gov

For more information contact:
Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

January 2010

AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis

A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; astrid.hilde.myrset@algipharma.com

September 2009